Schroder Investment Management Group Lowers Stake in United Therapeutics Co. (NASDAQ:UTHR)

Schroder Investment Management Group trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 1.2% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 163,782 shares of the biotechnology company’s stock after selling 2,020 shares during the period. Schroder Investment Management Group owned 0.37% of United Therapeutics worth $58,575,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics in the 4th quarter valued at $25,000. Millstone Evans Group LLC purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB increased its stake in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the period. Jones Financial Companies Lllp raised its holdings in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in United Therapeutics in the fourth quarter valued at about $131,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $940,373.07. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,500 shares of company stock valued at $26,134,500 over the last 90 days. Insiders own 11.90% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Stock Performance

United Therapeutics stock opened at $308.27 on Tuesday. United Therapeutics Co. has a fifty-two week low of $221.53 and a fifty-two week high of $417.82. The stock has a fifty day moving average of $339.04 and a two-hundred day moving average of $355.62. The company has a market capitalization of $13.85 billion, a price-to-earnings ratio of 13.54, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter last year, the business posted $4.36 EPS. On average, analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.